Your session is about to expire
← Back to Search
Long Term Follow-up for RGX-202
N/A
Waitlist Available
Research Sponsored by REGENXBIO Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years inclusive of parent study
Awards & highlights
No Placebo-Only Group
Summary
RGX-202-5101 is a long-term follow up study that evaluates the long term safety and efficacy of RGX-202 in participants who have received RGX-202 (a gene therapy designed to deliver a transgene for novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain) in a separate parent study.
Eligible Conditions
- Duchenne Muscular Dystrophy
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 5 years inclusive of parent study
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years inclusive of parent study
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Evaluation of long-term safety of RGX-202
Secondary study objectives
Efficacy measured by change in Functional Assessment
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: RGX-202 RecipientsExperimental Treatment1 Intervention
Subjects who have received RGX-202 in a separate parent study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
No Intervention
2017
Completed Phase 1
~4810
Find a Location
Who is running the clinical trial?
REGENXBIO Inc.Lead Sponsor
24 Previous Clinical Trials
2,714 Total Patients Enrolled